Skip to main content
. Author manuscript; available in PMC: 2012 Jan 7.
Published in final edited form as: Biochem Biophys Res Commun. 2010 Dec 9;404(1):370–375. doi: 10.1016/j.bbrc.2010.11.125

Figure 1. Anisomycin treatment decreases ENT1 activity.

Figure 1

32Dp185 were incubated with 50ng/ml anisomycin for the times indicated. The values shown in the graphs represent means ± S.D. of data (A) ENT1-dependent 3[H]-Uridine uptake. (n=6, *p<0.05). (B) Immunoblot analysis for pJNK, pc-Jun (Ser73), total c-Jun and β–actin. Shown is a representative experiment of three separate experiments. (C) 32Dp185 ENT1-dependent 3[H]-Uridine uptake after 3h of 10, 30 and 50ng/ml anisomycin treatments, pretreated with or without 10µM SP600125 JNK inhibitor for 1h (n=3, *p<0.05 statistical significance compared to the corresponding SP600125+Anisomycin value, #p<0.05 statistical significance compared to control value). (D) Cells were treated with 10, 30 and 50ng/ml anisomycin (A) for 3h pretreated with or without 10 µM SP600125 (SP) JNK inhibitor for 1h. Immunoblot analysis for pJNK, pc-Jun (Ser73), total c-Jun and total JNK. Shown is an experiment representative of three separate experiments.